Transient headache exacerbation during IV dihydroergotamine (DHE) therapy of migraine may prompt clinicians to prematurely discontinue DHE therapy, potentially depriving patients of the full benefit of DHE infusion. In a recent Neurology ® article, Eller et al. evaluated whether or not worsening headache during DHE infusion was associated with suboptimal medium-term headache outcomes. Neurology ® 2016;87:e196-e198
This Journal Club reviews an article by Eller et al. 1 investigating the relationship between transient headache worsening during dihydroergotamine (DHE) infusion and medium-term headache benefit among patients with chronic migraine (CM).
The use of IV DHE in CM was first reported by Raskin in 1986, 2 who used an average dose of 0.7 mg repeated every 8 hours over 48 hours. Given the poor bioavailability of DHE, Nagy et al. 3 more recently studied the therapeutic effect of higher doses of IV DHE. The results of this study indicated superior outcomes for refractory CM patients who received higher doses of IV DHE, thus supporting the use of a 5-day protocol with a total dose of 11.25 mg. Overall, 75% of CM patients became headache-free at 1 month after DHE therapy. 3 Nausea is a common side effect of IV DHE therapy, thought to be secondary to its dopaminergic action. 3 Nausea affects 58% of patients and results in cessation of DHE infusion in 4%. 3 In addition, nausea is a significant predictor of failure to become pain-free. 3 Therefore, aggressive antiemetic therapy is recommended. 3 While nausea is a well-documented side effect of IV DHE therapy, it is also a part of the diagnostic criteria for migraine. 4 A significant proportion of patients undergoing DHE infusion also report worsening headache. 1,3 A similar phenomenon has been described with triptan use. 5 This may prompt clinicians to prematurely terminate the intervention, potentially depriving patients of the full benefit of DHE infusion. This study aimed to evaluate whether worsening headache during DHE infusion was associated with suboptimal medium-term headache outcome. METHODS This was a retrospective cohort study in which the medical records were reviewed for all CM patients admitted to UCSF for IV DHE therapy between 2008 and 2012. A previously published 5-day protocol was used, 3 including antiemetic pretreatment (ondansetron, domperidone, or both). Patients with comorbid medication overuse headache were included, and these patients received IV aspirin prior to DHE. Diagnoses of CM and medication overuse headache were made in accordance with the International Classification of Headache Disorders, 3rd edition, beta version (ICHD-III beta) criteria by utilizing patients' chart documentation. All patients were managed by one physician. Transient headache worsening during DHE infusion was defined as an increase in headache or nausea during or within 30 minutes of the infusion. These data were extracted from contemporaneous medical notes, as well as headache diaries maintained by the patients during their admission. Patients were not routinely questioned about transient headache worsening during the DHE infusion.
Medium-term headache benefit was the primary outcome variable, and was assessed at 6-week follow-up by the patient's response to the question "Did you derive any benefit in terms of your headache from the treatment?" RESULTS Headache outcome data were available for 214 CM patients. Of these patients, 78% had medium-term headache benefit following DHE treatment and 19% had headache exacerbation. Patients with headache exacerbation had less (66%) medium-term headache benefit when compared to those who had medium-term benefit but did not have headache exacerbation (82%). Using a univariate logistic regression model, it was determined that headache exacerbation with DHE infusion was associated with reduced odds of obtaining medium-term headache benefit (odds ratio [OR] 0.43, p 5 0.03). However, using a multivariate logistic regression analysis, which was adjusted for other risk factors such as nausea, leg cramping, medication overuse, sex, and age, it was reported that headache exacerbation following DHE treatment could no longer independently predict medium-term headache benefit (OR 0.65, p 5 0.31).
Further examination of the risk factors included in the multivariate analysis revealed that nausea had the largest impact on the OR estimate, since its removal from the model resulted in a slight change from the marginal estimate (OR 0.51, p 5 0.09). In contrast, this OR estimate change did not occur when leg cramping (OR 0.65, p 5 0.31) or medication overuse (OR 0.61, p 5 0.24) were removed from the model. Furthermore, the presence of nausea was significantly associated with headache exacerbation with DHE infusions (OR 11.4, p 5 0.02), and was an independent predictor of lower likelihood of obtaining medium-term headache benefit in a fully adjusted model (OR 0.12, p 5 0.05). Medication overuse was also determined to be an independent predictor (OR 0.42, p 5 0.04). Of the remaining risk factors, older age was associated with a 68% increased odds of obtaining benefit with each decade increase in age (OR 1.68, p 5 0.001), and post hoc visual data inspection determined that patients in their teens and 20s were the least likely to benefit from DHE treatment. INTERPRETATION Based on their study, Eller et al. 1 concluded that headache exacerbation during or within 30 minutes of DHE infusion should not mandate for infusion discontinuation. The authors made this conclusion based on the absence of association between DHE infusion headache exacerbation and medium-term headache outcome.
Strengths of this study include the following: Limitations of this study include the following:
1. Study design: The study method lacked sample size computation, study power, statistical significance level and direction, and effect size. Convenience sampling was employed from a 4-year interval. Although easier to conduct, convenience sampling is vulnerable to underrepresentation or overrepresentation of particular cohorts. 6 One can ask what the reason was to limit the study timespan to that specific 4-year period. 2. Data abstraction, data reliability, and representativeness: Data abstractors were not mentioned. It is generally recommended to have a minimum of 2 data abstractors when conducting chart reviews 7 to assess interrater reliability. It was not clear whether data abstractors were blinded to the study question. Not all patients were interviewed regarding headache exacerbation during DHE infusion; this created additional selection bias. That all included patients were seen by a single physician could make the results difficult to generalize for real-world practice. External validity testing at multicenter studies will enhance the implementability of this study for widespread recommendations.
3. Recall bias: Interviewing patients at 6 weeks after DHE infusion using a single question as the sole assessment method could create recall bias. This could be avoided by utilizing daily headache diaries. 4. Statistics: The confidence interval (CI) of the multivariate regressed OR measuring association between nausea during DHE infusion and medium-term headache outcome contained the null value 1-this indicated insufficient evidence to conclude that the association was statistically significant. However, the interpretation put forward by the authors was the reverse. Furthermore, the wide CI for the univariate OR measuring association between nausea and headache exacerbation (OR 11.4, 95% CI 1.51-86.15) indicated higher uncertainty; this could have been avoided by computing adequate sample size. 5. Nausea: The authors used worsening of headache or nausea to define transient headache exacerbation, then they separated headache from nausea in their analysis. This was difficult to interpret as both headache and nausea are parts of the ICHD-III-beta diagnostic criteria for migraine. 4 Separating nausea caused by migraine from that caused by DHE infusion could be challenging.
FUTURE DIRECTIONS This article supports continuing therapy of DHE infusion despite headache worsening; the authors also recommend proactive antiemesis management since nausea was found to be associated with poor medium-term headache outcome. An alternative way to obviate the occurrence of nausea during DHE administration is by using nasally and orally inhalable DHE preparations; the former is available commercially while the latter is currently undergoing clinical trials. 8, 9 Inhalable DHE administrations have lower nausea effect and this has been explained as a consequence of reduced maximal serum concentrations compared to the IV form. 9
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